Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for patency of permanent hemodialysis catheters
IRCT20221220056873N1Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of aspirin in end-stage kidney disease (ESKD) (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoint: Extending the patency of permanent hemodialysis catheters. Started Apr 2023; status: completed.
02
Drugs
aspirin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20221220056873N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221220056873N1.